Strategic Partnerships Newomics actively collaborates with electrophoresis experts (e.g., Advanced Electrophoresis Solutions) and is launching joint CE-MS interfaces, signaling a sales opportunity to partner with distributors and integrators in CE-MS workflows and to cross-sell multi-spray technology to existing AES customers.

Targeted Events Plans to present at major conferences like ASMS 2026 indicate visibility to mass spectrometry users; leverage event participation to schedule introductions with lab managers, instrument specialists, and procurement teams seeking higher sensitivity and throughput solutions.

Platform Expansion Product launches such as FSK-AM splitter and UniESI SEED program demonstrate a strategy to integrate with existing LC-MS setups; explore opportunities with high-flow LC adopters and Bruker, Thermo, and other major system users for compatibility adjacencies and upgrade cycles.

Market Fit Small company with a focus on low sample amounts and high sensitivity positions Newomics to target clinics, metabolomics labs, and biomarker discovery groups that require robust MS interfaces; pursue pilot projects and case studies to validate ROI for small-to-mid scale labs.

Financial Upsell Current revenue bracket and $16M funding suggest a favorable environment for tiered pricing, pilot licenses, and multi-year support contracts; propose bundled offerings combining MEA-based ion sources, CE-MS interfaces, and service packages to accelerate adoption and recurring revenue.